Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
14 avr. 2022 07h10 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
31 mars 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...
Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022
23 mars 2022 08h30 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress
16 mars 2022 08h37 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...